title: Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants.
abstract: Virus-like particles (VLPs) are a promising vaccine platform due to the safety and efficiency. However, it is still unclear whether polyomavirus-based VLPs are useful for this purpose. Here, we attempted to evaluate the potential of polyomavirus VLPs for the antiviral vaccine using simian virus 40 (SV40). We constructed chimeric SV40-VLPs carrying an HLA-A*02:01-restricted, cytotoxic T lymphocyte (CTL) epitope derived from influenza A virus. HLA-A*02:01-transgenic mice were then immunized with the chimeric SV40-VLPs. The chimeric SV40-VLPs effectively induced influenza-specific CTLs and heterosubtypic protection against influenza A viruses without the need of adjuvants. Because DNase I treatment of the chimeric SV40-VLPs did not disrupt CTL induction, the intrinsic adjuvant property may not result from DNA contaminants in the VLP preparation. In addition, immunization with the chimeric SV40-VLPs generated long-lasting memory CTLs. We here propose that the chimeric SV40-VLPs harboring an epitope may be a promising CTL-based vaccine platform with self-adjuvant properties.
authors: Department of Allergy and Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan.
authors: Masaaki
authors: M
authors: Kawano
authors: Katsuma
authors: K
authors: Morikawa
authors: Tatsuya
authors: T
authors: Suda
authors: Naohito
authors: N
authors: Ohno
authors: Sho
authors: S
authors: Matsushita
authors: Toshitaka
authors: T
authors: Akatsuka
authors: Hiroshi
authors: H
authors: Handa
authors: Masanori
authors: M
authors: Matsui
mesh_terms: D000818:Animals; D002678:Chimera / Q000235:genetics / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D006801:Humans; D007109:Immunity; D007114:Immunization; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology* / Q000502:physiology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology* / Q000502:physiology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D051379:Mice; D008822:Mice, Transgenic; D013539:Simian virus 40 / Q000235:genetics* / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014764:Viral Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D018984:Epitopes, T-Lymphocyte; D007252:Influenza Vaccines; D014764:Viral Proteins
keywords: Adjuvant; Cytotoxic T lymphocyte; Influenza A virus; Polyomavirus; SV40; Vaccine; Virus-like particles